Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neurologica Belgica
Published in: Acta Neurologica Belgica 2/2014

01-06-2014 | Letter to the Editor

Safety of intravenous recombinant tissue plasminogen activator in recent trauma

Authors: Zabeen Mahuwala, Archana Hinduja

Published in: Acta Neurologica Belgica | Issue 2/2014

Login to get access

Excerpt

Intravenous recombinant tissue plasminogen activator (tPA) is the only drug approved for acute ischemic stroke with a well-established safety and efficacy profile [1]. However, the major limiting factors in using this are the narrow therapeutic window and the extensive exclusion criteria. A large number of these exclusion criteria are based on expert opinion and lack scientific basis and hence unjustifiable. Modification of the exclusion criteria could increase the rate of thrombolysis to 20 % [2]. We report the safety of administration of intravenous tPA for acute stroke in a patient with recent pelvic fracture. …
Literature
1.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333(24):1581–1587CrossRef
2.
Tong D (2011) Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine. Neurology 76(21):1780–1781PubMedCrossRef
Metadata
Title
Safety of intravenous recombinant tissue plasminogen activator in recent trauma
Authors
Zabeen Mahuwala
Archana Hinduja
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Acta Neurologica Belgica / Issue 2/2014
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-013-0258-7

Other articles of this Issue 2/2014

Acta Neurologica Belgica 2/2014 Go to the issue

Original Article

Delayed intravenous thrombolysis based on MRI mismatch in posterior circulation stroke

Letter to the Editor

Plus–minus lid syndrome caused by thalamic hematoma

Original Article

Quantitative and qualitative evaluation tool in planning stroke treatment strategies: the “Safe implementation of treatments in stroke Monitoring Study (SITS MOST)” registry

Review Article

Imaging predictors of outcome following intravenous thrombolysis in acute stroke

Original Article

Clinical efficacy and sEMG analysis of a new traditional Chinese medicine therapy in the treatment of spasticity following apoplectic hemiparalysis

Neuro-Images

Unilateral hand flapping as warning sign of stroke